SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 328 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $731,409,357 | +16.0% | 6,033,735 | +9.6% | 0.02% | +23.5% |
| Q2 2023 | $630,256,925 | -13.4% | 5,503,466 | +4.2% | 0.02% | -19.0% |
| Q1 2023 | $728,113,851 | +2.5% | 5,282,695 | -3.6% | 0.02% | -4.5% |
| Q4 2022 | $710,379,070 | +20.4% | 5,482,166 | +2.7% | 0.02% | +10.0% |
| Q3 2022 | $589,985,000 | +40.4% | 5,337,304 | -4.8% | 0.02% | +53.8% |
| Q2 2022 | $420,352,000 | -3.0% | 5,607,663 | +1.1% | 0.01% | +8.3% |
| Q1 2022 | $433,329,000 | -9.0% | 5,546,959 | +5.0% | 0.01% | 0.0% |
| Q4 2021 | $475,935,000 | +8.1% | 5,285,234 | +11.0% | 0.01% | 0.0% |
| Q3 2021 | $440,224,000 | +16.4% | 4,760,218 | -2.2% | 0.01% | +9.1% |
| Q2 2021 | $378,310,000 | -7.9% | 4,866,351 | -11.7% | 0.01% | -8.3% |
| Q1 2021 | $410,924,000 | -55.2% | 5,513,550 | +2.5% | 0.01% | -58.6% |
| Q4 2020 | $917,103,000 | +19.7% | 5,379,215 | -1.4% | 0.03% | +3.6% |
| Q3 2020 | $766,128,000 | -11.1% | 5,455,591 | +1.6% | 0.03% | -17.6% |
| Q2 2020 | $861,306,000 | +80.2% | 5,371,735 | +9.9% | 0.03% | +47.8% |
| Q1 2020 | $478,088,000 | -20.2% | 4,887,444 | +5.3% | 0.02% | 0.0% |
| Q4 2019 | $598,783,000 | +76.4% | 4,640,285 | +3.0% | 0.02% | +64.3% |
| Q3 2019 | $339,373,000 | -43.1% | 4,505,741 | +14.9% | 0.01% | -44.0% |
| Q2 2019 | $596,029,000 | +19.4% | 3,922,543 | -6.3% | 0.02% | +13.6% |
| Q1 2019 | $499,081,000 | -5.6% | 4,187,264 | -13.6% | 0.02% | -18.5% |
| Q4 2018 | $528,758,000 | -31.9% | 4,845,231 | +0.8% | 0.03% | -20.6% |
| Q3 2018 | $776,581,000 | +25.3% | 4,808,259 | +2.6% | 0.03% | +17.2% |
| Q2 2018 | $619,564,000 | +38.0% | 4,687,256 | -22.7% | 0.03% | +38.1% |
| Q1 2018 | $449,089,000 | +28.4% | 6,061,409 | -3.6% | 0.02% | +23.5% |
| Q4 2017 | $349,773,000 | +23.8% | 6,286,343 | +0.9% | 0.02% | +21.4% |
| Q3 2017 | $282,499,000 | +60.6% | 6,227,910 | +19.3% | 0.01% | +55.6% |
| Q2 2017 | $175,947,000 | +12.3% | 5,219,442 | -1.4% | 0.01% | 0.0% |
| Q1 2017 | $156,664,000 | +4759.3% | 5,292,729 | +4403.1% | 0.01% | +80.0% |
| Q4 2016 | $3,224,000 | -52.0% | 117,536 | +7.6% | 0.01% | -50.0% |
| Q3 2016 | $6,710,000 | +1833.7% | 109,280 | +500.6% | 0.01% | +900.0% |
| Q2 2016 | $347,000 | +478.3% | 18,196 | +499.3% | 0.00% | – |
| Q1 2016 | $60,000 | +13.2% | 3,036 | +122.7% | 0.00% | – |
| Q4 2015 | $53,000 | -94.3% | 1,363 | -95.3% | 0.00% | -100.0% |
| Q3 2015 | $923,000 | +2697.0% | 28,733 | +2550.6% | 0.00% | – |
| Q2 2015 | $33,000 | +106.2% | 1,084 | -9.4% | 0.00% | – |
| Q1 2015 | $16,000 | -5.9% | 1,196 | 0.0% | 0.00% | – |
| Q4 2014 | $17,000 | -32.0% | 1,196 | 0.0% | 0.00% | – |
| Q3 2014 | $25,000 | -30.6% | 1,196 | 0.0% | 0.00% | – |
| Q2 2014 | $36,000 | +24.1% | 1,196 | -0.2% | 0.00% | – |
| Q1 2014 | $29,000 | +26.1% | 1,198 | +5.6% | 0.00% | – |
| Q4 2013 | $23,000 | -53.1% | 1,134 | +9.2% | 0.00% | – |
| Q3 2013 | $49,000 | +22.5% | 1,038 | 0.0% | 0.00% | – |
| Q2 2013 | $40,000 | – | 1,038 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |